Non-small cell lung cancer, RET-positive
Revision as of 17:21, 12 October 2020 by Warner-admin (talk | contribs) (Text replacement - "][" to "] [")
Page editor | Section editor | ||
---|---|---|---|
Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN AmitKulkarniMD |
Travis Osterman, DO, MS Vanderbilt University Nashville, TN TravisOsterman |
Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
7 regimens on this page
7 variants on this page
|
Advanced or metastatic disease
Selpercatinib monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Evidence |
---|---|
Drilon et al. 2020 (LIBRETTO-001) | Phase I/II (RT) |
Biomarker eligibility criteria
- RET fusion positive
Chemotherapy
- Selpercatinib (Retevmo) with or without food, as follows:
- Less than 50 kg: 120 mg PO twice per day
- 50 kg or more: 160 mg PO twice per day
Continued indefinitely
References
- LIBRETTO-001: Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Aug 27;383(9):813-824. link to original article PubMed NCT03157128